Actively Recruiting
Deprescribing Inappropriate Proton Pump Inhibitors
Led by University of Bern · Updated on 2026-05-14
400
Participants Needed
2
Research Sites
169 weeks
Total Duration
On this page
Sponsors
U
University of Bern
Lead Sponsor
S
Swiss National Science Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The DROPIT Trial is an interventional, open-labelled, cluster-randomized controlled trial conducted in the Swiss primary care setting. It aims to evaluate an intervention to guide the deprescribing of inappropriate proton-pump inhibitors (PPIs). Therefore, the trial investigates whether the study intervention leads to the deprescribing of inappropriate PPI prescription while ensuring noninferiority safety, in comparison to usual care. Additionally, the trail aims to investigate the intervention's impact on other clinical aspects, as well as addressing features of the implementation of the intervention and its cost-effectiveness.
CONDITIONS
Official Title
Deprescribing Inappropriate Proton Pump Inhibitors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient of a participating general practitioner (GP).
- Age 18 years or older.
- Daily proton pump inhibitor (PPI) intake for at least 8 weeks.
- PPI dose at or above minimum levels: 40mg/day pantoprazole, 40mg/day omeprazole, over 30mg/day lansoprazole, over 30mg/day dexlansoprazole, over 20mg/day esomeprazole, or over 20mg/day rabeprazole.
- Sufficient knowledge of the German language to understand the trial and follow-up as assessed by the GP.
You will not qualify if you...
- Limited life expectancy less than 12 months according to GP judgment.
- Unable to provide informed consent.
- PPI prescribed at an appropriate dose with an established long-term indication such as history of bleeding ulcer, peptic ulcer not caused by NSAID or H. pylori, Barrett's oesophagus, severe erosive reflux disease (Los Angeles grade C/D), gastroesophageal reflux disease (GERD) with symptoms or complications, or other specified conditions (e.g., Zollinger-Ellison syndrome).
- Use of two or more of the following medications, or one medication plus one or more risk factors: daily NSAIDs for more than 7 days, antiplatelet therapy, additional antiplatelet therapy (e.g., ticagrelor), anticoagulants, systemic steroids for over 1 month.
- Risk factors include history of gastrointestinal ulcer, age 75 years or older, use of SSRIs or SNRIs, or severe concomitant disease increasing gastrointestinal bleeding risk (e.g., severe liver disease, neoplasia, nicotine or alcohol abuse).
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Prof. Dr. med. Dr. phil. Sven Streit
Bern, Switzerland, 3012
Not Yet Recruiting
2
University of Bern
Bern, Switzerland, 3012
Actively Recruiting
Research Team
S
Sven Streit, Prof. Dr med. Dr. phil.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here